These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancers. Yagi T, Inoue N, Yanai A, Murase K, Imamura M, Miyagawa Y, Enomoto Y, Nishimukai A, Takatsuka Y, Hirota S, Akazawa K, Miyoshi Y. Breast Cancer; 2016 Mar; 23(2):224-30. PubMed ID: 25082658 [Abstract] [Full Text] [Related]
5. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer. Jang N, Kwon HJ, Park MH, Kang SH, Bae YK. Ann Surg Oncol; 2018 Apr; 25(4):937-946. PubMed ID: 29330719 [Abstract] [Full Text] [Related]
6. Relation between Ki-67, ER, PR, Her2/neu, p21, EGFR, and TOP II-α expression in invasive ductal breast cancer patients and correlations with prognosis. Yan J, Liu XL, Han LZ, Xiao G, Li NL, Deng YN, Yin LC, Ling LJ, Yu XY, Tan CL, Huang XP, Liu LX. Asian Pac J Cancer Prev; 2015 Apr; 16(2):823-9. PubMed ID: 25684532 [Abstract] [Full Text] [Related]
7. Ki67 Frequency in Breast Cancers without Axillary Lymph Node Involvement and its Relation with Disease-free Survival. Shandiz FH, Shabahang H, Afzaljavan F, Sharifi N, Tavasoli A, Afzalaghaee M, Roshanzamir E, Pasdar A. Asian Pac J Cancer Prev; 2016 Apr; 17(3):1347-50. PubMed ID: 27039770 [Abstract] [Full Text] [Related]
10. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013. Ehinger A, Malmström P, Bendahl PO, Elston CW, Falck AK, Forsare C, Grabau D, Rydén L, Stål O, Fernö M, South and South-East Swedish Breast Cancer Groups. Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648 [Abstract] [Full Text] [Related]
15. Prognostic significance of preoperative 18F-FDG PET/CT for breast cancer subtypes. Higuchi T, Nishimukai A, Ozawa H, Fujimoto Y, Yanai A, Miyagawa Y, Murase K, Imamura M, Takatsuka Y, Kitajima K, Fukushima K, Miyoshi Y. Breast; 2016 Dec; 30():5-12. PubMed ID: 27569020 [Abstract] [Full Text] [Related]
16. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery. Pata G, Guaineri A, Bianchi A, Amoroso V, Pasinetti N, Pasini M. J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768 [Abstract] [Full Text] [Related]
19. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases. Peng L, Zhang Z, Zhao D, Zhao J, Mao F, Sun Q. Pathol Oncol Res; 2021 Apr; 27():599894. PubMed ID: 34257555 [Abstract] [Full Text] [Related]
20. Hormone receptor and HER2 status in patients with breast cancer by races in southeastern Turkey. Kuzhan A, Adli M, Eryigit Alkis H, Caglayan D. J BUON; 2013 Apr; 18(3):619-22. PubMed ID: 24065473 [Abstract] [Full Text] [Related] Page: [Next] [New Search]